Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For the patient group in the long-term follow-up part of the study:
- People who are willing and able to give informed consent to take part
- Men or women between the ages of 40 and 80
- People who are generally in good health, or who have been diagnosed with type 2 diabetes for less than 10 years, with no signs of eye damage (retinopathy) or other diabetes-related complications
- People whose HbA1c blood sugar level is 7% or higher
For the healthy comparison group in the long-term follow-up part of the study:
- People who are willing and able to give informed consent to take part
- Men or women between the ages of 40 and 80
- People who are generally in good health and have not been diagnosed with type 2 diabetes
For the snapshot (cross-sectional) part of the study:
- People who are willing and able to give informed consent to take part
- Men or women between the ages of 40 and 80
- People who have been diagnosed with type 2 diabetes for more than 20 years, with or without signs of eye damage (retinopathy) or other diabetes-related complications
- People whose HbA1c blood sugar level is 7% or higher
Who may not be able to join:
- People with eye or whole-body conditions other than diabetes
- People with high blood pressure (readings above 140/90 mmHg)
- People with anaemia (a low red blood cell level, measured as a haematocrit below 35%)
- People who currently smoke
- People who have had laser eye treatment, or who are pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
imaging assessment (OCT, Optical coherence tomography; OCT-A, Optical Coherence Tomography Angiography and Dynamic Vessel Analyzer); confocal microscopy, blood sampling collection and conjunctival impression cytology
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.